Body Protective Compound 157 - Lenvima (Lenvatinib) Interaction
Herbal: Body Protective Compound 157
Also Known As: BPC 157, BPC-157
Drug: Lenvatinib
Brand names:
Lenvima
Medical Content Editor Dr. Brian Staiger, PharmD
Last updated
Jun 22, 2025
Interaction Details
There were no interactions found between Lenvatinib and Body Protective Compound 157. This does not mean the potential for an interaction does not exist, however. There is often a lack of studies and data surrounding traditional medicine, especially concerning drug interactions, so it is important to always consult your provider before making any changes to your medication regimen.
Body Protective Compound 157 Overview
BPC 157, also known as body protective compound 157 and Bepecin , is a pentadecapeptide derived from human gastric juice. It has attracted significant interest for its potential therapeutic benefits in addressing various musculoskeletal and soft tissue injuries. This peptide has been shown to expedite the healing of tendons, ligaments, and skeletal muscles in numerous preclinical studies. BPC 157 facilitates cell survival, migration, and proliferation, primarily through the activation of the FAK-paxillin pathway and upregulation of growth hormone receptors.
Research has indicated that BPC 157 can significantly enhance the outgrowth of tendon fibroblasts, improve wound closure, and stimulate reepithelialization and collagen deposition in skin injuries. Importantly, it has demonstrated effectiveness in models of both traumatic and systemic injuries, indicating a wide range of potential applications.
While promising results have been observed in rodent models, the translation of BPC 157's benefits to human clinical applications is still in the early stages.
Lenvatinib Overview
-
Lenvatinib is used to treat a certain type of thyroid cancer that has returned or that has spread to other parts of the body and cannot be treated with radioactive iodine. Lenvatinib is also used along with everolimus (Afinitor, Zortress) to treat renal cell carcinoma (RCC, a type of cancer that begins in the kidney) in people who have previously received treatment with another chemotherapy medication. Lenvatinib is also used along with pembrolizumab (Keytruda) as an initial treatment for advanced renal cell carcinoma. Lenvatinib is also used to treat hepatocellular carcinoma (HCC; a type of liver cancer) that cannot be treated with surgery. Lenvatinib is also used along with pembrolizumab (Keytruda) to treat a certain type of cancer of the endometrium (lining of the uterus) that has spread to other parts of the body or worsened during or after treatment with chemotherapy medications or that cannot be treated with surgery or radiation therapy. Lenvatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.
Body Protective Compound 157 - More Interactions
Body Protective Compound 157 interacts with 0 drugs
Interaction Rating Key
These severity listings are for informational use only. Never start, stop or otherwise change your therapy before speaking with your provider.
| Major | The combined use of these agents is strongly discouraged as serious side effects or other negative outcomes could occur. |
| Moderate | Use cautiously under the care of a healthcare professional or avoid this combination. A significant interaction or negative outcome could occur. |
| Minor | Be aware that there is a chance of an interaction. Watch for warning signs of a potential interaction. |
| Unknown | No interactions have been reported or no interaction data is currently available. |
Return to the main supplement interaction checker page
Parts of this content are provided by the Therapeutic Research Center, LLC.
DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.
© 2021 Therapeutic Research Center, LLC
Drug descriptions are provided by MedlinePlus.
Ask A Pharmacist About Your Herbal Questions!
Dr. Brian Staiger, PharmD
In addition to being a clinical pharmacist specializing in pharmacotherapy, Dr. Brian Staiger is a registered herbalist through the American Herbalist Guild. He has combined his passion for pharmacy practice with the study of medical ethnobotany to improve patient care. Feel free to reach out about any of your herbal or medication questions!
Ask A Pharmacist